Stemnovate aims to commercialize platforms that reduce the cost of drug discovery for the pharmaceutical industry and ensure safety for the patients.
Pharmaceutical companies need timely and actionable insights from their drug discovery data to enter clinical trials. Medical practitioners need to ensure patient safety from adverse drug reactions. However, they are often constrained by the technology that has huge reliability on animal testing. Thereby wasting effort and opportunities while increasing risk of failure at the clinical trials or post-marketing.
Stemnovate compliant platforms are integrating somatic stem cell models ‘on a chip’ as the novel bioengineered solution for drug-screening and safety-testing.
If you’re looking for a rewarding career with an organisation that’s passionate about reshaping drug discovery landscape, we want to hear from you.